Virginia A. Schad, PharmD, RPh, Author at Infectious Disease Advisor - Page 6 of 8
Virginia A. Schad, PharmD, RPh

Virginia A. Schad, PharmD, RPh

Contributing Writer
Virginia A. Schad, PharmD, RPh, is a contributing medical author for the Haymarket Medical Network, part of the Medical Communications Group of Haymarket Media. She earned her Doctor of Pharmacy degree at the University of Pittsburgh in Pittsburgh, Pennsylvania, in 1999. For the past 20 years, Dr Schad has worked in medical communications developing numerous presentations, as well as slide libraries and kits, and editing journal articles and supplements, clinical study reports, product monographs, and program abstracts. She has also organized and implemented speaker training meetings, consultants’ meetings, advisory board meetings, roundtable meetings, and CME symposia. While Dr Schad has worked in many therapeutic areas, her areas of focus have been in endocrinology, infectious diseases, pulmonology, neurology, and cardiology.

All articles by Virginia A. Schad, PharmD, RPh

Liver cancer, CT scan of abdomen

Sustained Virologic Response in Patients With Chronic Hepatitis C and Liver Cancer

In Hong Kong, researchers found data from 49 studies that were conducted in 15 countries in patients with chronic hepatitis C and hepatocellular carcinoma (HCC) or without HCC, which showed that overall, the sustained virologic response rate for direct-acting antiviral therapy was approximately 90%. In addition, they found that in patients with HCC who were treated with any sofosbuvir-based regimen had lower sustained viral response rates than the sustained viral response rates of patients without HCC who were treated with sofosbuvir-based regimens.

Patient-Reported Symptoms During and After Direct Acting Antiviral Therapy for HCV

From a real-world study, researchers observed that patients with hepatitis C who received direct-acting antiviral medications did not experience significant changes in symptoms during treatment, except in 1346 patients who were cured and reported improvements in fatigue; sleep disturbance; and functional well-being, including pain and depression.

Pile of pills, medicine, prescriptions

Elbasvir/Grazoprevir: First-Line Therapy for Chronic HCV in DAA-Naive Patients?

Researchers found data that showed that in patients who were direct-acting antiviral treatment- naive the nonstructural protein 5A inhibitor elbasvir combined with the NS3/4A protease inhibitor grazoprevir is safe and effective for hepatitis C genotype 1 infection, having a sustained viral response at 12 weeks post-treatment. They also noted that this should be a first-line treatment.

Next post in Hepatitis Advisor